Catalog No.
RHC90101
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
FCM: 1:20-1:100, IF: 1:50-1:200, WB: 1:1000-1:2000
Target
CYP2C9, Cytochrome P450 PB-1, Cytochrome P450 MP-8, (S)-limonene 7-monooxygenase, CYP2C10, (S)-limonene 6-monooxygenase, (R)-limonene 6-monooxygenase, S-mephenytoin 4-hydroxylase, Cholesterol 25-hydroxylase, Cytochrome P450 2C9, Cytochrome P450 MP-4, CYPIIC9, Cytochrome P-450MP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11712
Applications
FCM, IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1N45
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease., PMID:39707077
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model., PMID:39285155
[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis]., PMID:39093141
Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis., PMID:38984761
An in silico investigation of the toxicological effects and biological activities of 3-phenoxybenzoic acid and its metabolite products., PMID:38833509
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab., PMID:38044486
Targeted Metabolomics Study of Human Plasma Revealed Activation of the Cytochrome P450 Epoxygenase/Epoxide Hydrolase Axis in Patients with IgA Nephropathy., PMID:36301320
Spontaneous Spinal Epidural Hematoma During Simultaneous Tocilizumab and Warfarin Use in a Patient With Rheumatoid Arthritis: Is There a Drug Interaction Between Tocilizumab and Oral Anticoagulants?, PMID:33758819
Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5., PMID:32968106
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab., PMID:32407591
Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes., PMID:32131538
Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium., PMID:31616008
Effect of Dietary Doses of Quercetin on Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats., PMID:31065969
Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes., PMID:30732170
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis., PMID:30574672
CYP2J2 is the major enzyme in human liver microsomes responsible for hydroxylation of SYL-927, a novel and selective sphingosine 1-phosphate receptor 1 (S1P1 ) agonist., PMID:30362120
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab., PMID:29498038
The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An in Vitro Study., PMID:28867723
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)., PMID:28817838
Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study., PMID:28248857
Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes., PMID:27924364
Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol., PMID:27836712
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach., PMID:26991517
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6., PMID:26961818
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes., PMID:26894931
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity., PMID:26451330
CYP450 Enzyme-Mediated Metabolism of TCAS and Its Inhibitory and Induced Effects on Metabolized Enzymes in Vitro., PMID:26404338
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole., PMID:26228688
Dietary Doses of Sulforaphane Affect Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats., PMID:26084424
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach., PMID:26054042
Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain., PMID:25504503
Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine., PMID:25138712
The development of humanized liver with Rag1 knockout rats., PMID:24815157
Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys., PMID:24593267
Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions., PMID:24485758
Isoniazid hepatotoxicity: progress in understanding the immunologic component., PMID:24037911
In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies., PMID:23992115
In vitro identification of cytochrome P450 enzymes responsible for drug metabolism., PMID:23824861
Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure., PMID:23775837
Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies., PMID:23165723
Genome-wide association study of antibody response to smallpox vaccine., PMID:22542470
Interleukin-6 and cytochrome-P450, reason for concern?, PMID:22451032
Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans., PMID:22023129
Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys., PMID:21849623
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes., PMID:21704641
In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone., PMID:21532165
The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression., PMID:21493749
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome., PMID:21371740
Bullous allergic drug eruption with presence of myeloperoxidase and reorganization of the dermal vessels observed by using CD34 and collagen IV antibodies., PMID:22540071
Metabolism of sesamin by cytochrome P450 in human liver microsomes., PMID:20851877
For research use only. Not for human or drug use.
